Donald McCaffrey
Chief Executive Officer en RESVERLOGIX CORP. .
Fortuna: 613 356 $ al 31/03/2024
Perfil
Donald J.
McCaffrey is the founder.
He founded Resverlogix Corp.
in 2000, where he currently holds the titles of Chairman, President, CEO & Secretary.
He also founded Zenith Capital Corp.
(Alberta) in 2013, where he currently holds the titles of Chairman, President & Chief Executive Officer.
In addition to his founding positions, Mr. McCaffrey has held former positions as Director at Trillium Therapeutics ULC from 2004 to 2006, and as Director at ProMIS Neurosciences, Inc.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ZENITH CAPITAL CORP.
1.72% | 02/01/2024 | 2 615 324 ( 1.72% ) | 392 299 $ | 31/03/2024 |
RESVERLOGIX CORP.
1.93% | 02/01/2024 | 5 263 266 ( 1.93% ) | 221 057 $ | 31/03/2024 |
Cargos activos de Donald McCaffrey
| Empresas | Cargo | Inicio |
|---|---|---|
| RESVERLOGIX CORP. | Chief Executive Officer | 25/04/2003 |
| ZENITH CAPITAL CORP. | Chief Executive Officer | 10/04/2013 |
Antiguos cargos conocidos de Donald McCaffrey.
| Empresas | Cargo | Fin |
|---|---|---|
| TRILLIUM THERAPEUTICS | Director/Board Member | 27/03/2006 |
| PROMIS NEUROSCIENCES, INC. | Director/Board Member | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| RESVERLOGIX CORP. | Health Technology |
| ZENITH CAPITAL CORP. | Health Technology |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
- Bolsa de valores
- Insiders
- Donald McCaffrey
